Deep Pharma Intelligence Ltd

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—4

Registered number: 12987888

		2026		2025
	Notes	£	£	£	£
FIXED ASSETS
Intangible Assets	4		294,233		294,233

			294,233		294,233
CURRENT ASSETS
Debtors	5	6,294		4,795
Cash at bank and in hand		-		2,392

		6,294		7,187
Creditors: Amounts Falling Due Within One Year	6	(352,203 )		(347,147 )

NET CURRENT ASSETS (LIABILITIES)			(345,909 )		(339,960 )

TOTAL ASSETS LESS CURRENT LIABILITIES			(51,676 )		(45,727 )

NET LIABILITIES			(51,676 )		(45,727 )

CAPITAL AND RESERVES
Called up share capital	7		10,000		10,000
Profit and Loss Account			(61,676 )		(55,727 )

SHAREHOLDERS' FUNDS			(51,676)		(45,727)

Page 1

Page 2

Deep Pharma Intelligence Ltd

Balance Sheet (continued)

As At 31 March 2026

For the year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Mr. I Inkster

Director

02/07/2026

The notes on pages 3 to 4 form part of these financial statements.

1. General Information

Deep Pharma Intelligence Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 12987888 . The registered office is 63-66 Hatton Garden, 5th Floor, Suite 23, London, EC1N 8LE.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Research and Development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research is recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised to ... on a straight line basis over their expected useful economic lives, which range from ... to ... years.

If it is not possible to distinguish between the research phase and the development phase of an internal project the expenditure is treated as if it were all incurred in the research phase only.

2.3. Foreign Currencies

Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.

3. Average Number of Employees

Average number of employees, including directors, during the year was: 1 (2025: 1)

4. Intangible Assets

	Development Costs
	£
Cost
As at 1 April 2025	326,926

As at 31 March 2026	326,926

Amortisation
As at 1 April 2025	32,693

As at 31 March 2026	32,693

Net Book Value
As at 31 March 2026	294,233

As at 1 April 2025	294,233

Page 3

Page 4

Deep Pharma Intelligence Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 March 2026

5. Debtors

	2026	2025
	£	£
Due within one year
Trade debtors	3,350	3,350
Other debtors	2,944	1,445

	6,294	4,795

6. Creditors: Amounts Falling Due Within One Year

	2026	2025
	£	£
Trade creditors	12,844	12,844
Other creditors	358,720	353,039
Taxation and social security	(19,361 )	(18,736 )

	352,203	347,147

7. Share Capital

	2026	2025
	£	£
Allotted, Called up and fully paid	10,000	10,000

Page 4